Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion type Assertion NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_head.
- NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion description "[Protein modulation was investigated in OA cartilage explants treated with a specific PAR-2-activating peptide (PAR-2-AP), SLIGKV-NH2 (1 to 400 microM), interleukin 1 beta (IL-1beta) (100 pg/mL), tumor necrosis factor-alpha (TNF-alpha) (5 ng/mL), transforming growth factor-beta-1 (TGF-beta1) (10 ng/mL), or the signalling pathway inhibitors of p38 (SB202190), MEK1/2 (mitogen-activated protein kinase kinase) (PD98059), and nuclear factor-kappa B (NF-kappaB) (SN50), and PAR-2 levels were determined by immunohistochemistry.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_provenance.
- NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion evidence source_evidence_literature NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_provenance.
- NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion SIO_000772 18031579 NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_provenance.
- NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion wasDerivedFrom befree-20140225 NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_provenance.
- NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_assertion wasGeneratedBy ECO_0000203 NP387351.RAG9ly_YmlZLQULlM5vDIt4_lnX9Y5hNo0iYquf4mT4XM130_provenance.